Collaboration Agreements (Tables)

3 Months Ended

Mar. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration Revenues and Contract Assets and Liabilities

Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):



	Three Months Ended March 31,
	2018		2017
Ipsen collaboration revenues	$	53,809	$	4,530

Royalty revenues on ex-U.S. sales and our share of the profits and losses recognized in connection with COTELLIC’s commercialization in the U.S. were as follows (in thousands):



	Three Months Ended March 31,
	2018		2017
Royalty revenues on ex-U.S. sales	$	1,349	$	2,298
Profits and losses on U.S. commercialization	$	1,373	$	(626	)

Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):



	Three Months Ended March 31,
	2018		2017
Royalties accruing to GSK	$	5,125	$	2,737

Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):



	Three Months Ended March 31,
	2018		2017
Takeda collaboration revenues	$	2,917	$	2,682